The NF-κB Activation Inhibitor III, also referenced under CAS 380623-76-7, controls the biological activity of NF-κB. This small molecule/inhibitor is primarily used for Inflammation/Immunology applications.
Synonym(s):
NF-κB Activation Inhibitor III, 3-Chloro-4-nitro-N-(5-nitro-2-thiazolyl)-benzamide, SM-7368
A cell-permeable inhibitor of TNF-α-stimulated NF-κB activation and subsequent upregulation of MMP-9 in HT1080 cells (complete inhibition at 10 µM). The inhibition of MMP-9 upregulation correlates with a concomitant inhibition of TNF-α-dependent cell invasion. Does not affect TNF-α-induced AP-1 activity. The cellular target appears to be downstream of p38 activation.
A cell-permeable thiazoloamide compound that inhibits TNF-α-stimulated NF-κB activation and subsequent upregulation of MMP-9 in HT1080 cells (complete inhibition at 10 µM). The inhibition of MMP-9 upregulation correlates with a concomitant inhibition of TNF-α-dependent cell invasion. Does not affect TNF-α-induced AP-1 activity. The cellular target appears to be downstream of p38 activation.
Biochem/physiol Actions
Cell permeable: yes
Effective concentration: 10 µM for complete inhibition of TNF-α-stimulated NF-κB activation and subsequent upregulation of MMP-9 in HT1080 cells
Primary Target TNF-α-stimulated NF-κB activation and upregulation of MMP-9
Product does not compete with ATP.
Reversible: no
Packaging
Packaged under inert gas
Warning
Toxicity: Irritant (B)
Other Notes
Lee, H.Y., et al. 2005. Biochem. Biophys. Res. Commun.336, 716.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Topoisomerase inhibitors are clinically used to treat various cancer types, including colorectal cancer. These drugs also activate signaling pathways that modulate cell survival and immune cell functions. Immunotherapy is promising for certain tumors, including microsatellite instable colorectal cancer, but not
Journal of molecular and cellular cardiology, 88, 133-144 (2015-10-10)
Inflammation is central to heart failure progression. Innate immune signaling increases expression of the transmembrane proteoglycan syndecan-4 in cardiac myocytes and fibroblasts, followed by shedding of its ectodomain. Circulating shed syndecan-4 is increased in heart failure patients, however the pathophysiological
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
